A team of investigators conducted a systematic review and meta-analysis to assess the risk of extraintestinal cancer in patients with inflammatory bowel disease.
Researchers compared the predictive properties of the IBDDI from among 5populations of individuals living with IBD, most of whom had Crohn disease as well.
Investigators evaluated data on lipid levels and cardiovascular events in addition to recommendations for managing lipid levels during tofacitinib treatment in patients with ulcerative colitis, according to up-to-date expert guidelines.
Histo-endoscopic mucosal healing after induction therapy of ustekinumab is associated with lower disease activity at the conclusion of maintenance therapy.
Researchers studied the histologic and clinical features of primary sclerosing cholangitis patients with and without IBD to predict disease severity.
Researchers assessed malignancy frequency in the tofacitinib ulcerative colitis clinical development program, along with frequency of malignancy events and rates.
Although cannabis use does not induce clinical remission in IBD, patient-reported quality of life may improve.
An AI-powered, fully automated video analysis system may potentially provide endoscopic disease grading in ulcerative colitis that is equal to the scoring of experienced reviewers.
A longitudinal cohort study was conducted to validate the IBD-F scale in the assessment of clinically significant fatigue, as well as to identify the impact of fatigue on quality of life in patients with IBD.
This is the first study to report polymorphisms associated with long term response to anti-TNF treatment in pediatric patients with Crohn disease and ulcerative colitis.
A team of investigators sought to identify risk factors associated with colorectal cancer in patients with ulcerative colitis.
Etrolizumab is an investigational humanized monoclonal anti-ß7 antibody designed to selectively inhibit α4β7 and αEβ7 integrins.
Study finds that patients with IBD and 1 or more comorbidities are at increased risk for viral or bacterial meningitis.
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.
A team of investigators conducted a systematic review to estimate the risk of relapse in patients with ulcerative colitis in remission.
Patients with inflammatory bowel disease had a similar risk for and outcomes from coronavirus disease 2019 as those in the general population.
Vitamin D may be used to reduce the risk of immune checkpoint inhibitor-related colitis, as well as ulcerative colitis and graft-vs-host disease.
The majority of endoscopic modalities for ulcerative colitis (UC) neoplasia surveillance were similarly effective, but white light standard definition (WL SD) was the least so.
Researchers evaluated the association of psoriasis and psoriatic arthritis with inflammatory bowel disease and other gastrointestinal illnesses.
Probiotics should only be recommended for specific patient populations since there is not enough evidence to support their use in the majority of digestive conditions, according to new clinical guidelines released by the American Gastroenterological Association (AGA) and recently published in Gastroenterology.